Umifenovir sulfoxide | CAS# 151455-33-3 | Biochemical

MedKoo Cat#: 574983 | Name: Umifenovir sulfoxide

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Umifenovir sulfoxide is the oxidative metabolite of umifenovir, an antiviral drug. It inhibits the fusion of the influenza virus with host cell membranes by binding to the hemagglutinin protein, preventing viral entry. Used primarily in Russia and China, umifenovir treats and prevents influenza and has been investigated for potential COVID-19 treatment.

Chemical Structure

Umifenovir sulfoxide

CAS#151455-33-3

Theoretical Analysis

MedKoo Cat#: 574983

Name: Umifenovir sulfoxide

CAS#: 151455-33-3

Chemical Formula: C22H25BrN2O4S

Exact Mass: 492.0718

Molecular Weight: 493.42

Elemental Analysis: C, 53.55; H, 5.11; Br, 16.19; N, 5.68; O, 12.97; S, 6.50

Price and Availability

Size	Price	Availability	Quantity

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Arbidol sulfoxide; Umifenovir sulfoxide; Umifenovir metabolite M6

IUPAC/Chemical Name

1H-Indole-3-carboxylic acid, 6-bromo-4-((dimethylamino)methyl)-5-hydroxy-1-methyl-2-((phenylsulfinyl)methyl)-, ethyl ester

InChi Key

CTIGWEMWZSPYAS-UHFFFAOYSA-N

InChi Code

InChI=1S/C22H25BrN2O4S/c1-5-29-22(27)20-18(13-30(28)14-9-7-6-8-10-14)25(4)17-11-16(23)21(26)15(19(17)20)12-24(2)3/h6-11,26H,5,12-13H2,1-4H3

SMILES Code

CCOC(=O)c1c(C[S+]([O-])c2ccccc2)n(C)c3cc(Br)c(O)c(CN(C)C)c13

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 493.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Gao Y, Zhao Y, Liu M, Luo S, Chen Y, Chen X, Zheng Q, Xu J, Shen Y, Zhao W, Li Z, Huang S, Huang J, Tian J, Guyatt G, Hao Q. Antiviral Medications for Treatment of Nonsevere Influenza: A Systematic Review and Network Meta-Analysis. JAMA Intern Med. 2025 Mar 1;185(3):293-301. doi: 10.1001/jamainternmed.2024.7193. PMID: 39804622; PMCID: PMC11877164. 2: Jung H, Park JY, Yoon D, Kang DY, Jung J, Kim JH, Shin JY. Patient-Reported Adverse Events Among Elderly Patients Receiving Novel Oral COVID-19 Antivirals: A Nationwide Sampled Survey in Korea. J Korean Med Sci. 2024 Oct 28;39(41):e270. doi: 10.3346/jkms.2024.39.e270. PMID: 39468947; PMCID: PMC11519057. 3: Zheng J, Chen C, Huang Y, Fang S, Guo P, Liu S, Ouyang G. A fast solid-phase microextraction scheme for in vivo monitoring of bio-accumulation and bio- transformation of arbidol in living plants. Sci Total Environ. 2024 Dec 15;956:177175. doi: 10.1016/j.scitotenv.2024.177175. Epub 2024 Nov 5. PMID: 39461518. 4: Kozlov KV, Maltsev OV, Kasyanenko KV, Sukachev VS, Lyashenko YI, Kosuhina AA. [Comparative assessment of the clinical effectiveness of direct-acting antiviral drugs in outpatient patients with acute respiratory viral infections]. Ter Arkh. 2024 Sep 14;96(8):797-803. Russian. doi: 10.26442/00403660.2024.08.202911. PMID: 39404725. 5: Zou Y, Peng P, Zou H, Zhang Y, Chen C, Huang S. Transport and retention of COVID-19-related antiviral drugs in saturated porous media under various hydrochemical conditions. Ecotoxicol Environ Saf. 2024 Oct 15;285:117028. doi: 10.1016/j.ecoenv.2024.117028. Epub 2024 Sep 13. PMID: 39276648. 6: Mia ME, Howlader M, Akter F, Hossain MM. Preclinical and Clinical Investigations of Potential Drugs and Vaccines for COVID-19 Therapy: A Comprehensive Review With Recent Update. Clin Pathol. 2024 Jul 26;17:2632010X241263054. doi: 10.1177/2632010X241263054. PMID: 39070952; PMCID: PMC11282570. 7: Li M, Jin Y, Wu J, Zhao M, Yu K, Yu H. Arbidol, an antiviral drug, identified as a sodium channel blocker with anticonvulsant activity. Br J Pharmacol. 2024 Nov;181(21):4311-4327. doi: 10.1111/bph.16496. Epub 2024 Jul 9. PMID: 38982721. 8: Freidel MR, Vakhariya PA, Sardarni SK, Armen RS. The Dual-Targeted Fusion Inhibitor Clofazimine Binds to the S2 Segment of the SARS-CoV-2 Spike Protein. Viruses. 2024 Apr 20;16(4):640. doi: 10.3390/v16040640. PMID: 38675980; PMCID: PMC11054727. 9: Ren Y, Chen Y, Tang EH, Hu Y, Niu B, Liang H, Xi C, Zhao F, Cao Z. Arbidol attenuates liver fibrosis and activation of hepatic stellate cells by blocking TGF-β1 signaling. Eur J Pharmacol. 2024 Mar 15;967:176367. doi: 10.1016/j.ejphar.2024.176367. Epub 2024 Feb 6. PMID: 38325795. 10: Pan S, Mou C, Chen Z. Red recombination enables a wide variety of markerless manipulation of porcine epidemic diarrhea virus genome to generate recombinant virus. Front Cell Infect Microbiol. 2024 Jan 22;13:1338740. doi: 10.3389/fcimb.2023.1338740. PMID: 38317792; PMCID: PMC10839022. 11: Korula P, Alexander H, John JS, Kirubakaran R, Singh B, Tharyan P, Rupali P. Favipiravir for treating COVID-19. Cochrane Database Syst Rev. 2024 Feb 5;2(2):CD015219. doi: 10.1002/14651858.CD015219.pub2. PMID: 38314855; PMCID: PMC10840071. 12: Guo Z, He H, Yang G, Liu K, Xi Y, Li Z, Luo Y, Liao Z, Dao G, Ren X, Huang B, Pan X. The environmental risks of antiviral drug arbidol in eutrophic lake: Interactions with Microcystis aeruginosa. J Hazard Mater. 2024 Mar 15;466:133609. doi: 10.1016/j.jhazmat.2024.133609. Epub 2024 Feb 1. PMID: 38310846. 13: Rojek B, Bartyzel A, Sawicki W, Plenis A. DSC, TGA-FTIR and FTIR Assisted by Chemometric Factor Analysis and PXRD in Assessing the Incompatibility of the Antiviral Drug Arbidol Hydrochloride with Pharmaceutical Excipients. Molecules. 2024 Jan 4;29(1):264. doi: 10.3390/molecules29010264. PMID: 38202847; PMCID: PMC10780367. 14: Rosli NB, Kwon HJ, Jeong JS. Simultaneous quantification method for multiple antiviral drugs in serum using isotope dilution liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2023 Dec 1;1231:123925. doi: 10.1016/j.jchromb.2023.123925. Epub 2023 Nov 19. PMID: 37992562. 15: Guo Z, He H, Liu K, Yang S, Li Z, Lai C, Liao Z, Ren X, Huang B, Pan X. Sunlight-induced degradation of COVID-19 antivirals arbidol in natural aquatic environments: Mechanisms, pathways and toxicity. J Environ Manage. 2023 Dec 1;347:119113. doi: 10.1016/j.jenvman.2023.119113. Epub 2023 Sep 26. PMID: 37769471. 16: Bai X, Xi S, Chen G, Fan X, Wang K, Li Y, Zhao Y, Wang W, Tian Y. Multicenter, randomized controlled, open label evaluation of the efficacy and safety of arbidol hydrochloride tablets in the treatment of influenza-like cases. BMC Infect Dis. 2023 Sep 6;23(1):585. doi: 10.1186/s12879-023-08570-9. PMID: 37674112; PMCID: PMC10483848. 17: Zhou H, Xie P, Qiu M, Dong S, Xia X, Yang Z, Yuan Y, Shen L. Arbidol increases the survival rate by mitigating inflammation in suckling mice infected with human coronavirus OC43 virus. J Med Virol. 2023 Sep;95(9):e29052. doi: 10.1002/jmv.29052. PMID: 37650132. 18: Kang Y, Shi Y, Xu S. Arbidol: The current demand, strategies, and antiviral mechanisms. Immun Inflamm Dis. 2023 Aug;11(8):e984. doi: 10.1002/iid3.984. PMID: 37647451; PMCID: PMC10461429. 19: Yi W, Jia C, Yang Z, Fan H, Li M, Lv Z. Effect of umifenovir (arbidol) versus standard care on clinical outcome in patients with COVID-19: a retrospective cohort study. Ther Adv Respir Dis. 2023 Jan- Dec;17:17534666231183811. doi: 10.1177/17534666231183811. PMID: 37395539; PMCID: PMC10328169. 20: Fan S, Wang H, Wu D, Liu L. Pharmaceutical approaches for COVID-19: An update on current therapeutic opportunities. Acta Pharm. 2023 Jun 12;73(2):157-173. doi: 10.2478/acph-2023-0014. PMID: 37307372.